Peptide profile · Weight Management
Mazdutide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
Molecular formula
C210H322N46O67
- CAS number
- 2259884-03-0
- PubChem
- 167312357
- Developed · 2023
- Eli Lilly and Innovent Biologics, Eli Lilly and Company / Innovent Biologics
Amino acid sequence
37-amino acid oxyntomodulin analog with Aib2 substitution and C18 diacid fatty acid acylation via PEG2 linker at Lys101.5 – 6mg
Every documented dose level
| Phase | Dose | Frequency |
|---|---|---|
| Initial titration weeks | 1.5 mg | Once weekly |
| Weeks 32-48 | 4 mg | Once weekly |
| Weeks 32-48 | 6 mg | Once weekly |
Best for individuals seeking substantial weight loss exceeding 15% body weight & adults with type 2 diabetes requiring superior glycemic management
Best for
Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Known hypersensitivity to mazdutide or any formulation excipients
- History of severe pancreatitis
- Severe renal impairment (eGFR <15 mL/min) without clinical data
Use with caution if
- You are taking other medications—discuss potential interactions with your healthcare provider
- You have a history of liver or kidney disease
- You are elderly or have multiple medical conditions
- You are planning surgery in the near future—inform your surgeon about Mazdutide use
- You have any chronic health conditions that require regular monitoring
Not sure?
Compare Mazdutide with similar peptides to find the best fit for your goals.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- Front of thighs—middle to upper portion of the outer leg
- Back of upper arm—outer area (may need assistance from another person)
The Mazdutide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.
3 common side effects · 2 serious
Mazdutide (Innovent/Lilly GLP-1 and glucagon dual agonist) is approved in China for weight management and type 2 diabetes.
Its safety profile is dominated by gastrointestinal side effects, mostly mild to moderate. Nausea/vomiting occur in 40-50% of subjects at higher doses; weight loss averaging 12-18% observed.
Pancreatitis risk monitoring required; calcitonin was monitored, with no values of 20 ng/L or higher in phase 2. Heart rate increases 5-9 bpm; no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Phase 1b and phase 2 data show HbA1c reductions (1.2-1.8%) and weight loss superior to GLP-1 monotherapy. Mechanistic studies using indirect calorimetry show increased energy expenditure and fat oxidation.
Pancreatic imaging via MRI shows no structural abnormalities; serum lipase monitored for pancreatitis risk. On electrocardiograms in phase 2, cardiac findings were mild, asymptomatic and transient, most often sinus tachycardia (2.8% with mazdutide vs 3.2% with placebo).
Common side effects · experienced by some users
Nausea
Most commonly reported adverse event, particularly during titration. Typically transient and self-limiting within 2-4 weeks .
Management
Slow dose titration, eat smaller meals, avoid high-fat foods, and stay hydrated.
Serious side effects
Acute Pancreatitis
Rare but serious complication reported with GLP-1 class agents. Presents with severe persistent abdominal pain .
Management
Discontinue mazdutide immediately. Seek emergency medical care. Do not rechallenge after confirmed pancreatitis.
Acute Cholecystitis and Biliary Disease
Rapid weight loss and increased biliary cholesterol mobilization from adipose tissue can precipitate gallstone formation and acute cholecystitis, particularly in genetically predisposed individuals .
Management
Screen for gallbladder disease history before treatment; consider preventive ursodeoxycholic acid during rapid weight loss phases; monitor for right upper quadrant pain; educate on symptoms; ensure adequate fat intake (prevents bile stasis); surgical consultation if acute symptoms develop.
Severe Nausea and Gastrointestinal Intolerance
Dual GLP-1/GcgR activation combined with hepatic metabolic effects can cause severe nausea, vomiting, abdominal pain, and GI distress particularly during dose escalation, potentially requiring hospitalization.
Management
Use slower titration schedule; take with food; avoid fatty meals; consider antiemetics; adequate hydration essential; slower dose escalation than tirzepatide may be necessary; monitor for dehydration complications.
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Mazdutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Mazdutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- SafeMetformin — May be used together under medical guidance.
- SafeStructured Exercise Program — May be used together under medical guidance.
- SafeSGLT2 Inhibitors — May be used together under medical guidance.
With medications
- CautionOther GLP-1 Receptor Agonists — Use with caution—discuss with your healthcare provider.
- CautionSulfonylureas — Use with caution—discuss with your healthcare provider.
- CautionInsulin (without dose reduction) — Use with caution—discuss with your healthcare provider.
With supplements
- SafeMultivitamins — Generally safe to take alongside Mazdutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Strong human trials · first signs weeks 1-4
Evidence level
Strong human trials
(Phase 3 or FDA approved)
100/100
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Mazdutide is a dual-action peptide that activates both glucagon receptors and GLP-1 receptors in your body, creating a synergistic weight loss effect more powerful than either mechanism alone.
It suppresses appetite through GLP-1 activation and increases metabolic rate through glucagon receptor activation, producing greater fat mobilization and weight loss compared to single-target GLP-1 drugs .
The deeper mechanism
Mazdutide is a synthetic peptide agonist that simultaneously activates glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R), both Gs-coupled GPCRs that increase cAMP and activate PKA signaling.
GLP-1R activation in hypothalamic POMC neurons suppresses appetite and increases satiety signaling, while GcgR activation in hepatocytes and adipocytes increases gluconeogenesis, lipolysis, and fatty acid oxidation, increasing metabolic rate and energy expenditure.
The dual agonism produces synergistic weight loss exceeding either mechanism alone: GLP-1 pathway provides appetite suppression (~15-20% weight loss), while GcgR activation provides metabolic acceleration (~8-12% additional weight loss), with combined effects potentially exceeding 20-25% weight loss in clinical trials.
Glucose-dependent insulin secretion enhancement occurs through both pathways, providing glycemic control benefits.
What to expect
Weeks 1-4
What you might notice
- Titration phase at 3 mg
- Early appetite reduction and mild gastrointestinal adjustment
- Initial weight loss of 2-4% typically observed
What's normal
- Full integration of Mazdutide into physiological systems is established
- Long-term Mazdutide response remains personalized to your physiology
- Mazdutide tolerance is well-maintained with consistent dosing
What's next
- Maintain your established Mazdutide protocol for sustained benefits
- Continue periodic monitoring to confirm Mazdutide efficacy
- Review comprehensive Mazdutide response with your provider
Weeks 4-16
What you might notice
- Dose escalation to 4.5-6 mg
- Progressive weight loss accelerates to 8-12%
- Significant HbA1c reductions become apparent in diabetic patients
What's normal
- Mazdutide is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Mazdutide's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Mazdutide dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Weeks 16-48+
What you might notice
- Maintenance at 6-9 mg
- Weight loss continues toward plateau of 15-20%
- Metabolic parameters stabilize with sustained improvements in lipids, liver fat, and blood pressure
What's normal
- Full therapeutic effects of Mazdutide are well-characterized at this point
- Maintenance of Mazdutide's therapeutic effects is typical
- Tolerance patterns with Mazdutide are generally stable over months
What's next
- Comprehensive assessment of Mazdutide efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Mazdutide over time
- Reduction in symptom frequency or severity
Signs it's working
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results?
Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
41 registered studies, 20 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 11,035 people took part in the studies that actually administered Mazdutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
Tongji Hospital
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
Yanbing Li
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Tianjin Medical University
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Mazdutide is named as an intervention; studies that only mention it in passing are not.
How does mazdutide differ from semaglutide?
Mazdutide is a dual GLP-1/glucagon receptor agonist, while semaglutide selectively targets only the GLP-1 receptor. The additional glucagon receptor activation in mazdutide increases hepatic fat oxidation and energy expenditure, potentially offering enhanced weight loss and liver fat reduction. In the DREAMS-3 head-to-head trial, mazdutide demonstrated statistically superior HbA1c reductions compared to semaglutide 1 mg .
Is mazdutide approved by the FDA?
As of early 2026, mazdutide is not FDA-approved. It received approval from China's NMPA in June 2025 for chronic weight management and in September 2025 for type 2 diabetes, marketed as Xinermei. Regulatory submissions in other markets are anticipated based on ongoing global clinical programs .
What was the weight loss observed in clinical trials?
In the GLORY-2 Phase 3 trial, mazdutide 9 mg achieved up to 20.1% mean body weight loss over the treatment period in adults with obesity. Earlier Phase 2 studies showed dose-dependent weight loss ranging from approximately 10% to 17% across dose groups .
Does mazdutide require dose titration?
Yes. Mazdutide is initiated at 3 mg once weekly and gradually titrated upward through 4.5 mg and 6 mg to the target maintenance dose of up to 9 mg. This stepwise approach minimizes gastrointestinal side effects, particularly nausea and vomiting.
Can mazdutide be used for type 2 diabetes?
Yes. Mazdutide is approved in China for type 2 diabetes and has demonstrated superior HbA1c reductions compared to both dulaglutide and semaglutide in Phase 3 DREAMS trials. Its dual mechanism provides glycemic control through both enhanced insulin secretion and reduced hepatic glucose output .
What are the main advantages of dual receptor agonism?
Dual GLP-1/glucagon receptor agonism combines appetite suppression and glucose regulation from GLP-1 activation with increased energy expenditure, hepatic fat oxidation, and lipid metabolism enhancement from glucagon activation. This complementary mechanism may produce greater weight loss and more comprehensive metabolic improvement than selective GLP-1 agonists alone .
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Mazdutide, on one page.
Mazdutide dosing protocol